Natco Pharma provides update on its marketing partner Mylan

U.S. Patent and Trademark Office rules in favour of Mylan

Natco Pharma announced that U.S. Patent and Trademark Office has ruled in favour of its marketing partner, Mylan, in its inter partes review (IPR) proceeding and found all claims of two related Copaxone 40 mg/mL patents to be un-patentable.

Natco's marketing partner, Mylan believes its is one of the first companies to have filled a substantially complete abbreviated new drug application containing Paragraph IV certification for a three times per week Glatiramer Acetate Injection 40 mg/ ML and expects to be eligible for 180 days of marketing exclusivity in the U.S. upon final FDA approval.

 

Powered by Capital Market - Live News